These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance]. Campos A; Aznar L; Alamar R; Castelló JV Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023 [No Abstract] [Full Text] [Related]
6. Case of anaphylaxis and four cases of allergic reaction following Gd-DTPA administration. Salonen OL J Comput Assist Tomogr; 1990; 14(6):912-3. PubMed ID: 2229566 [TBL] [Abstract][Full Text] [Related]
7. Fatal reaction to gadopentetate dimeglumine. Jordan RM; Mintz RD AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905 [No Abstract] [Full Text] [Related]
8. [A case of anaphylactic shock following the administration of Gd-DTPA]. Nomura M; Takeshita G; Katada K; Nakamura M; Kizukuri T; Ogura Y; Anno H; Koga S Nihon Igaku Hoshasen Gakkai Zasshi; 1993 Dec; 53(12):1387-91. PubMed ID: 8108244 [TBL] [Abstract][Full Text] [Related]
10. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine. Witte RJ; Anzai LL AJNR Am J Neuroradiol; 1994 Mar; 15(3):523-4. PubMed ID: 8197951 [TBL] [Abstract][Full Text] [Related]
12. Laryngospasm after administration of gadopentetate dimeglumine. Omohundro JE; Elderbrook MK; Ringer TV J Magn Reson Imaging; 1992; 2(6):729-30. PubMed ID: 1446118 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190 [TBL] [Abstract][Full Text] [Related]
14. Severe adverse reaction to iv gadopentetate dimeglumine. Takebayashi S; Sugiyama M; Nagase M; Matsubara S AJR Am J Roentgenol; 1993 Mar; 160(3):659. PubMed ID: 8430574 [No Abstract] [Full Text] [Related]
15. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial. Niendorf HP; Haustein J; Louton T; Beck W; Laniado M Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134 [No Abstract] [Full Text] [Related]
16. Pruritus and paresthesia after i.v. administration of Gd-DTPA. Chan K; Bosanko CM; Wang AM AJNR Am J Neuroradiol; 1989; 10(5 Suppl):S53. PubMed ID: 2505565 [No Abstract] [Full Text] [Related]
17. In vitro histamine release induced by magnetic resonance imaging and iodinated contrast media. Baxter AB; Lazarus SC; Brasch RC Invest Radiol; 1993 Apr; 28(4):308-12. PubMed ID: 7683008 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous nodules, pain, and thrombophlebitis as an adverse reaction to gadolinium contrast media. Murphy KJ; Hansen R; Prince MR AJR Am J Roentgenol; 1997 Jul; 169(1):318-9. PubMed ID: 9207574 [No Abstract] [Full Text] [Related]
19. [Comparative studies of the tolerability of gadodiamide, dimeglumine gadopentetate and meglumine gadoterate in MRI tests of the central nervous system]. Chanalet S; Masson B; Boyer L; Laffont J; Bruneton JN J Radiol; 1995 Jul; 76(7):417-21. PubMed ID: 7473375 [TBL] [Abstract][Full Text] [Related]
20. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA]. Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]